Earnings Volatility Drives Celldex Therapeutics and These Stocks in a New Direction

  Google+ | + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Celldex Therapeutics, Inc. (NASDAQ:CLDX) had a loss and missed Wall Street’s expectations, AND came up short on beating the revenue expectation. Adjusted Earnings Per Share decreased to $-0.24 in the quarter versus EPS of $-0.23 in the year-earlier quarter. Revenue Decreased 51.74% to $970,000 from the year-earlier quarter.

Celldex Therapeutics, Inc. reported adjusted EPS loss of $0.24 per share. By that measure, the company missed the mean analyst estimate of $-0.22. It missed the average revenue estimate of $1.67 million.

CLDX 20130811

Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) had a loss and beat Wall Street’s expectations, AND beat the revenue expectation. Adjusted Earnings Per Share increased to $-0.09 in the quarter versus EPS of $-0.01 in the year-earlier quarter. Revenue Decreased 19.52% to $38.1 million from the year-earlier quarter.

Isis Pharmaceuticals, Inc. reported adjusted EPS loss of $0.09 per share. By that measure, the company beat the mean analyst estimate of $-0.21. It beat the average revenue estimate of $26.76 million.

ISIS 20130811

RTI Surgical, Inc. (NASDAQ:RTIX) had a loss and missed Wall Street’s expectations, AND came up short on beating the revenue expectation. Adjusted Earnings Per Share decreased to $0.00 in the quarter versus EPS of $0.05 in the year-earlier quarter. Revenue Decreased 6.42% to $42.3 million from the year-earlier quarter.

RTI Surgical, Inc. reported adjusted EPS of $0 per share. By that measure, the company missed the mean analyst estimate of $0.03. It missed the average revenue estimate of $42.34 million.

RTIX 20130811

Akorn Inc. (NASDAQ:AKRX) delivered a profit and beat Wall Street’s expectations, AND beat the revenue expectation. Adjusted Earnings Per Share increased 16.67% to $0.14 in the quarter versus EPS of $0.12 in the year-earlier quarter. Revenue Rose 21.66% to $77 million from the year-earlier quarter.

Akorn Inc. reported adjusted EPS income of $0.14 per share. By that measure, the company beat the mean analyst estimate of $0.13. It beat the average revenue estimate of $75.06 million.

AKRX 20130811

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) had a loss and missed Wall Street’s expectations, BUT beat the revenue expectation. Adjusted Earnings Per Share increased to $-26 in the quarter versus EPS of $-0.35 in the year-earlier quarter. Revenue Decreased 6.67% to $1.4 million from the year-earlier quarter.

Rigel Pharmaceuticals, Inc. reported adjusted EPS loss of $26 per share. By that measure, the company missed the mean analyst estimate of $-0.3. It beat the average revenue estimate of $0.

RIGL 20130811

Stocks with improving earnings metrics are worthy of your extra attention. In fact, “E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our CHEAT SHEET investing framework for this very reason. Don’t waste another minute – click here and get our CHEAT SHEET stock picks now.

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business